Valneva Se Stock Earnings Reports

Q1 2026 highlights: Valneva reported product sales of €30.5m and total revenues of €30.9m (down vs. prior year due to phasing of DoD deliveries, distribution partner changes and intentional wind-down of third‑party products). The quarter was dominated by the mixed Phase III Lyme (VLA15) readout: efficacy was clinically meaningful (>70%) and well tolerated, the first prespecified statistical criterion was not met while the second was met (lower bound >20%), and Pfizer is planning regulatory submissions. Given remaining uncertainty around Lyme, management is prioritizing cash containment. Cash at March 31 was ~€105m (pre‑April financing proceeds). Management has launched a cost‑reduction program including a 10%–15% global workforce reduction and targeting a 25%–35% reduction in operating expenses versus 2025. FY2026 guidance was revised: product sales now €135m–€150m and total revenues €145m–€160m, citing softer travel vaccine demand (geopolitical impacts) and other one‑offs in Q1. Gross margins were pressured by manufacturing transfer to the Almeida site, increased batch write‑offs, idle capacity and IXCHIQ contract/production-related costs; management expects margins to normalize later in 2026. R&D priorities continue: Pfizer‑led Lyme BLA path, ongoing Chikungunya commercialization/partnering (including large pilot campaign in Brazil and Butantan licensure), and near‑term Shigella readouts (children immunogenicity and a CHIM pilot efficacy study) expected over the summer. Key risks: regulatory/approval uncertainty for Lyme (Pfizer is leading filings), potential further travel market weakness impacting sales, manufacturing/CMC remediation timing for Almeida relative to U.S. supply, and execution of the restructuring.